Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Mach7 Technologies Ltd is engaged in enterprise imaging data sharing, storage, and interoperability for healthcare enterprises globally. The company's operating segment includes Software licenses and Professional services. It generates maximum revenue from the Software licenses segment. Geographically, it derives a majority of revenue from North America and also has a presence in the Middle East; Asia/Pacific and Europe, and other regions. The company's solutions include Management Studio; Diagnostic Studio; and Clinical Studio.
|20 Jan 2022||$0.76||$0.00||0.00%||83,397||$0.76||$0.76||$0.75|
|19 Jan 2022||$0.76||$-0.02||-2.56%||385,193||$0.78||$0.78||$0.76|
|18 Jan 2022||$0.78||$-0.02||-2.50%||146,471||$0.80||$0.80||$0.78|
|17 Jan 2022||$0.80||$-0.01||-1.23%||20,673||$0.81||$0.81||$0.79|
|14 Jan 2022||$0.81||$-0.02||-2.41%||154,986||$0.82||$0.82||$0.79|
|13 Jan 2022||$0.83||$0.03||3.77%||157,044||$0.80||$0.83||$0.78|
|12 Jan 2022||$0.80||$-0.01||-1.25%||126,250||$0.79||$0.80||$0.79|
|11 Jan 2022||$0.80||$0.00||0.00%||67,319||$0.79||$0.80||$0.79|
|10 Jan 2022||$0.80||$-0.01||-1.23%||213,191||$0.82||$0.82||$0.79|
|07 Jan 2022||$0.81||$0.03||3.85%||152,116||$0.79||$0.82||$0.79|
|06 Jan 2022||$0.78||$-0.04||-4.88%||505,477||$0.82||$0.82||$0.78|
|05 Jan 2022||$0.82||$-0.01||-1.20%||56,980||$0.83||$0.83||$0.82|
|04 Jan 2022||$0.83||$0.01||1.22%||85,658||$0.83||$0.85||$0.82|
|31 Dec 2021||$0.82||$0.01||1.23%||91,415||$0.81||$0.82||$0.81|
|30 Dec 2021||$0.82||$-0.01||-1.21%||19,354||$0.81||$0.83||$0.81|
|29 Dec 2021||$0.83||$0.01||1.23%||164,432||$0.80||$0.83||$0.80|
|24 Dec 2021||$0.81||$0.00||0.00%||221,439||$0.81||$0.82||$0.80|
|23 Dec 2021||$0.82||$-0.01||-1.22%||45,674||$0.82||$0.83||$0.81|
|22 Dec 2021||$0.82||$-0.01||-1.20%||38,992||$0.83||$0.84||$0.82|
|11 Nov 2021||David Chambers||Issued||35||$32,725||
Issue of options.
|11 Nov 2021||Eliot Siegel||Issued||25||$23,375||
Issue of options.
|11 Nov 2021||Mike Lampron||Issued||402||$376,042||
Issue of securities. 780,299 - Performance Rights
|11 Nov 2021||Robert Bazzani||Issued||25||$23,375||
Issue of options.
|11 Nov 2021||Philippe Houssiau||Issued||250||$233,750||
Issue of options.
|29 Sep 2021||David Chambers||Buy||21||$20,895||
On-market trade. Average price
As per announcement on 30/09/2021
|11 May 2021||David Chambers||Buy||37||$38,828||
On-market trade. As per announcement on 14/05/2021.
|30 Apr 2021||Mike Lampron||Buy||116||$20,416||
Exercise of options.
|30 Apr 2021||Mike Lampron||Sell||116||$140,744||
|30 Apr 2021||Mike Lampron||Exercise||116||$20,416||
Exercise of options.
|Mr David Chambers||Non-Executive DirectorNon-Executive Chairman||Aug 2018||
Mr Chambers has more than 30 years experience in the Healthcare and Life Science industry and a track record in healthcare IT systems through a series of senior executive roles in Australia, North America, Europe, and Asia. David up until recently acted as Managing Director, Asia-Pacific, of Allscripts Healthcare Solutions, a NASDAQ listed billion-dollar global leader in Healthcare Technology, retiring after close to seven years, on 30th June 2020. Prior to that David was General Manager, Asia and ANZ with Carestream Health. He was former chief executive of ASX-Listed health software business Pro Medicus Limited. David also served eleven years with Agfa Healthcare, including managing their Informatics group in Asia Pacific, and culminating in his elevation to Vice President of Agfa North America.
|Dr Eliot L Siegel||Non-Executive Director||Aug 2018||
Dr Siegel is currently Professor and Vice Chair of information systems at the University of Maryland School of Medicine, Department of Diagnostic Radiology, and the Chief of Radiology and Nuclear Medicine for the Veterans Affairs Maryland Healthcare System, both in Baltimore, MD as well as adjunct professor of computer science and biomedical engineering at the undergraduate campuses of the University of Maryland. Under his guidance, the VA Maryland Healthcare System became the first filmless healthcare enterprise in the World. He has written over 300 articles and book chapters about PACS (Picture Archiving and Communication Systems) and digital imaging, and has edited six books on the topic, including Filmless Radiology and Security Issues in the Digital Medical Enterprise. He has given more than 1,000 presentations throughout the world on a broad range of topics involving the use of computers in medicine and artificial intelligence. Dr. Siegel was symposium chairman for the Society of Photo-optical and Industrial Engineers (SPIE) Medical Imaging Meeting for three years and has been honored as a fellow in that organization as well as the American College of Radiology. He is also a Board member of Carestream Health, a billion-dollar global company in digital radiography and computed radiography systems and serves on numerous advisory boards in medical imaging.
|Mr Mike Lampron||Chief Operating OfficerChief Executive OfficerManaging Director||Mar 2019||
Mr Lampron have more than 20 years of experience in business and operational management for Healthcare IT companies, Mike brings a experience ranging from private start-up organizations as well as long established companies such as IBM and GE. Mike was previously the Chief Executive Officer for a National Teleradiology Company and has a proven ability to drive results through a combination of astute analysis, innovative execution and cross-functional teamwork.
|Mr Robert John Bazzani||Non-Executive Director||Jan 2020||
Mr Bazzani has spent the past 20 years with the global consulting firm KPMG, where he rose to the top and served as Chairman of KPMG Victoria, National Managing Partner for KPMG Australia's Enterprise Division and National Managing Partner for KPMG's M&A Division. Whilst in these roles, Rob was a member of KPMG's National Executive Committee (NEC), which oversees and is responsible for the Firm's turnover, strategic decision making, profitability and operations. Rob has a demonstrated record of leading and growing large scale and complex businesses. He has played a significant role in advising clients (public, private, and global subsidiaries) on commercial maters, public transitions, corporate governance, M&A and has engaged with Government and Regulators. With extensive experience in corporate advisory, Rob has deep commercial and industry knowledge across financial services, asset and wealth management, property, insurances and consumer & industrial markets.
|Mr Philippe Houssiau||Non-Executive Director||Jan 2021||
Mr Houssiau held a variety of executive roles as Partner with PriceWaterhouse and PwC, CEO of Agfa Healthcare, where he transitioned the business from being an Analog Film manufacturing outfit to become a world leader in Imaging and Health IT, CEO of Alliance Medical, the leading European Imaging Services Provider and CEO/ Chairman of the Rhapsody Healthcare Interoperability business, now Lyniate. Philippe also ran the CSC/DxC Healthcare business in the UK and Netherlands and held many board and Chair positions, in Imaging and Healthcare. He currently serves as the CEO of MAKSystem, the leading Blood Management Software company and as Chairman of Corilus (Primary Care). Philippe is based in Antwerp, Belgium.
|Ms Veronique Morgan-Smith||Company Secretary||Oct 2021||
|Jenni Pilcher||Chief Financial Officer & Company Secretary||
|Steve Rankin||Chief Product Officer||
|Veronique Morgan-Smith||Company Secretary||
|Sandhurst Trustees Ltd||37,232,085||15.74%|
|J P Morgan Nominees Australia Pty Limited||32,393,265||13.69%|
|National Nominees Limited||32,166,789||13.60%|
|Hsbc Custody Nominees (Australia) Limited||9,263,892||3.92%|
|Ubs Nominees Pty Ltd||4,756,201||2.01%|
|PT Dwi Satrya Utama||4,392,959||1.86%|
|Perco Group Pty Ltd||3,980,000||1.68%|
|Bpnt Pty Ltd||3,897,000||1.65%|
|Chew & Partners (Import & Export) Pte Ltd||2,900,074||1.23%|
|Albert Liong Pak-Fai||2,044,189||0.86%|
|BNP Paribas Noms Pty Ltd||2,031,228||0.86%|
|Citicorp Nominees Pty Limited||1,963,367||0.83%|
|Mr Ravindran Krishnan||1,771,437||0.75%|
|Ty Webb Pty Ltd||1,339,444||0.57%|
|HSBC Custody Nominees (Australia) Limited I||1,160,287||0.49%|
|Moggs Creek Pty Ltd||1,000,000||0.42%|
|62 Darlinghurst Road Pty Ltd||1,000,000||0.42%|
|Australian Executor Trustees Limited||996,134||0.42%|
|Citicorp Nominees Pty Limited I||963,285||0.41%|
|BNP Paribas Noms Pty Ltd I||878,146||0.37%|